11 16 ( ) 1 11 16 ( ) 2 11 17 ( ) 1 11 17 ( ) 2 41 11 16 ( ) 11 2 17 ( ) 11 17 ( ) 1 11 16 43 1 46 95 1 54 2 62 2 67 3 75 1 106 2 109 1 83 2 85 1 91 2 93 129 2 11 17 2 47 49 100 3 70 4 78 1 59 3 112 4 115 5 118 6 121 7 124 3 87 4 89 129
11 16 ( ) 1 11 16 1 08 45 10 25 1 S1-1 54 S1-2 55 1 2 1,3 4 1 1 2 3 1 1 2 3 4 S1-3 56 S1-4 57 S1-P1 Dual-targeting Photoimmunotherapy 58 S1-P2 diffuse-type 58 1,2 1,2 1,2 1,2 1 1 1 2 10 35 10 50 41 10 50 11 10 43 14 29
11 16 ( ) 1 11 20 12 10 1 83 LS-1 QOL 12 20 13 20 95 SP-1 96 SP-2 96 SP-3 97 SP-4 97 1,2 1,2 1,2 1,2 1,2 1 1 1 1 1 1 1 1 2 SP-5 GSK3 98 13 20 14 05 1 SL-1 46 The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 15
11 16 ( ) 1 14 05 15 45 2 S2-1 ips 62 S2-2 63 1 1,2 1 1 1 2 3 1 2 3 S2-3 LINE-1 64 S2-4 65 S2-P1 S2-P2 66 myomir family microrna 66 15 50 16 40 1 91 TS-1 16 29
11 16 ( ) 2 11 16 08 45 09 30 2 2 S2-O1 LINC00162 RNA HNRNPH1 5- -2-67 1,2 Liang Zong 1,2 1 2 1 1 2 S2-O2 Epstein-Barr 67 S2-O3 mir-143 HER2 68 1 1 1 1 1 2 1 1 2 S2-O4 68 1,2 1 1 2 2 3 3 3 2 1 1 2 3 S2-O5 oncogenic small nucleolar RNA oncsnor 69 1 1 1 1 1 1 1 1 1 1 Ajay Goel 2 1 1 2 Baylor Research Institute S2-O6 DNA 69 1 1 2 3 4 1 1 2 3 4 JPLT 09 30 10 15 1 1 O1-1 EVs 106 1,2 1,2,3 1,2 1,2 1,2 1,2 1 1 1 1 1 1 1 1 2 3 TR The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 17
O1-2 106 1 2 2 3 2 2 1,2 1 2 3 O1-3 MDSC 107 11 16 ( ) 2 O1-4 107 O1-5 RNA 108 1 2 2 1 1 2 O1-6 108 1 1 1 1 1 1 1 2 2 3 2,4 1 1 2 3 4 11 20 12 10 2 85 14 15 15 00 3 S3-O1 75 S3-O2 S3-O3 TP53 75 1 1 1 1 1 1,2,3 1 1 2 1 3 4 2 1 1 2 3 4 76 1 2 3 4 4 5 6 3 1 1 TI 2 3 4 5 6 18 29
POLE 76 11 2 16 S3-O4 ( ) 1 1 2 3 3 1 1 1 1 1 1 2 3 S3-O5 BRAF600E CDX2 77 1 1 1 1 1 1 Eric Fearon 2 1 1 2 S3-O6 77 1 Ann-Marie Patch 2 Katia Nones 2 1 1 Barbara Leggett 2 Nicola Waddell 2 1 Vicki Whitehall 2 1 1 2 QIMR Berghofer Medical Research Institute, Brisbane, Australia 15 00 15 45 2 2 O2-1 109 O2-2 hypermutator 109 1 3 1 1 1 1 2 2 1 4 1 2 3 4 O2-3 CIMP SWI/SNF 110 1,2 1 1 1 2 O2-4 110 O2-5 111 O2-6 111 1,2 1,2 1,2 1,2 1,2 1,2 1 1 1 1 1 1 1 1 1 2 The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 19
15 50 16 40 2 93 11 16 ( ) 2 20 29
18 00 1 1 16 45 11 16 P1-1 EP1 ONO-8539 130 1,2 3 1 4 1 1 1,5 1,6 1,5 1,5 1 1 2 3 RI 4 5 6 P1-2 130 1,2 3 1 1,4 1,5 1,2 1,2 1 2 1 1 2 3 RI 4 5 P1-3 / 131 1 2 J-FAPP Study IV 3 1 2 3 P1-4 131 1 1 1 2 1 3 4 2 4 1 1 2 3 4 P1-5 132 DUONG THANH TU 1 1 1 2 3 2 3 4 1 1 2 3 4 P1-6 132 1 1 2 3 2 1 1 TI 2 3 P1-7 133 1 2,1 1 1 1 1 1 1 1 1 1 1 1 2 11 16 ( ) The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 21
11 16 ( ) BRAF 133 P1-9 ARID1A MSI status/pd-l1 134 1 2 1 1 1 1 1 3 2 1 1 2 3 P1-10 134 1 2 2 2 1 1 1 2 2 1 1 2 P1-11 ARID1A 135 1 1 1 1 1 1 1 1 2 1 1 2 P1-12 microrna-449a 135 16 45 18 00 3 P3-1 142 1 1 1 2,3 1,3,4 1 2 3 AMED-CREST 4 P3-2 HMGB1 142 P3-3 PD-L1 HLA class 143 P3-4 143 22 29
144 P3-5 P3-6 CD36 144 P3-7 FAP 145 1,2 1 1,2 1,2 1,2 1 1 1 1,2 1 1 2 P3-8 NF-kappaB 145 1,3 2 4 1 5 1 1 1 2 1 1 2 3 4 5 P3-9 TP53 mutation 146 1 2 3 13 1 1 1 1 1 1 1 1 1 2 3 CPM P3-10 T 146 11 16 ( ) 16 45 18 00 5 1 P5-1 B C ER 150 1 2 1 1 1 1 1 1 1 1 2 P5-2 gemcitabine MAST4 AKT3 150 1 1 1 2 1 1 2 P5-3 151 1 1 2 1 1 2 The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 23
11 16 ( ) strain 151 P5-5 Conophylline 152 1 1 1 1 1 1 1 1 1 1 1 2 1 1 2 P5-6 152 P5-7 IL-6 153 1,2 1 1 1 1 1 1,2 1 1,2 1 1 2 16 45 18 00 7 1 P7-1 TP73 SMAD4 158 1,2 2 2 1 2 P7-2 chloride intracellular channel 3 CLIC3 158 1 1 1 1 1 2 2 2 1 1 2 P7-3 Fibroblast Growth Factor Receptor 2 159 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1 1 1 1 1 1 1 2 P7-4 159 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1 1 1 2 P7-5 circmto1 160 1,2 1 1,2 1,2 1,2 1 1 1 1 2 P7-6 AFP mirna 160 24 29
161 P7-7 1 1 1 1 1 1 2 1 1 2 P7-8 161 P7-9 ARID1A 162 1 1 1 1 1 1 1 2 1 1 2 P7-10 Osteoclast-like giant cell hamartomatous inverted polyp 162 1 1 1 1 1 1 1 1 2 1 1 2 P7-11 Homeobox C10 163 P7-12 podoplanin 163 11 16 ( ) The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 25
11 17 ( ) 1 11 17 1 08 40 10 20 3 S3-1 70 1 1 2 2 1 2 S3-2 71 1 2 1 2 1 1 3 4 4,5 4 1 2 1,6 1 2 3 4 5 6 S3-3 72 1 2 2 1 3 1 2 3 S3-4 73 S3-P1 74 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 1 2 S3-P2 74 1,2 1 1 3 4 5 6 7 8 9 9 1 1 1 9 1 2 3 4 5 6 7 8 9 26 29
11 17 ( ) 1 10 30 10 55 10 55 11 20 microrna microbiota 49 Stathmin1 51 1 2, 3 2 2 2 2 2 2 2 2 2 1, 2, 3 2 2,3 1 2 3 11 30 12 30 3 87 12 40 13 25 2 SL-2 47 NIH 13 35 15 15 4 S4-1 78 AMED-CREST S4-2 79 1, 2 2 2 2 2 3 2 2 2 1 2 1 2 3 S4-3 80 The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 27
S4-4 81 S4-P1 GSK3 82 1 2 1 1 1 1 1 1 1 1 1 2 15 25 16 40 RS-1 100 11 17 ( ) 1 RS-2 100 RS-3 BRAF V600E 101 RS-4 LED 101 RS-5 102 1 1 1 1 1 1,2 1 3 4 5 1,6 1 2 3 4 5 6 RS-6 PCR 102 1 2 1 1 1 1 1 1 1 1 1 2 RS-7 103 RS-8 Luciferase assay 103 1) 1,2) 3) 1) 1) 1) 1) 1) 4) 1) 1 2 3 4 28 29
11 17 ( ) 2 11 17 08 40 09 25 1 2 S1-O1 FBXW7 59 Navchaa Gombodorj 1 Takehiko Yokobori 1 Kengo Kuriyama 1 Yuji Kumakura 1 Tomonori Yoshida 1 Makato Sakai 1 Makato Sohda 1 Tatsuya Miyazaki 1 Hiroyuki Kuwano 1 Ken Shirabe 1,2 1 2 S1-O2 59 1 S1-O3 MEK 60 1,2 2 2 1 1 1 2 S1-O4 StageII/III 60 1 1 1 1 1 1 1 2 2 1,2 1 2 S1-O5 5MP1 MYC 61 S1-O6 PD-L1 61 09 25 10 10 4 1 O4-1 / 115 The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 29
O4-2 Pten 115 1 2 3 1 4 4 4 4 1 1 2 3 Vanderbilt University 4 O4-3 116 1 1 1 2 1 1 2 2 1 1 2 O4-4 116 1,2 1,2 2,6 2,3 Kaidiliavi Sulidan 2,4 2 1 1 1 1 2 2 1 1 2 3 4 5 6 O4-5 Tenascin-C 117 2 11 17 ( ) 2 O4-6 HE 117 1 1 2 1 1 1 1 3 1 4 4 4 1 4 1 1 1 1 1 2 3 4 11 30 12 30 4 89 13 35 14 20 3 O3-1 HPV DNA 112 1,2 2 3 2 1,2 1 1 1 1 2 1 2 3 4 30 29
11 17 ( ) 2 112 1,4 1,3 1 1 1 1 2 1 4 1 1 2 3 4 O3-3 CCL2/CCR2 113 1 1 1 1,2 1,2 1,2 1 1 1 1 1 2 O3-4 113 1,2 1 1 1 1 1 1 3 4 3 2 1 1 1 2 3 4 O3-5 Barrett 114 O3-6 Cellbed 3 114 1 2 1 1 2 O3-2 FGF5 14 20 14 55 5 2 O5-1 PD-1 118 1,2 2 2 2 2 2 3 1 2,4 5 5 5 1 2 3 4 5 O5-2 FOLFIRI+ramucirumab 118 O5-3 Celecoxib Cyclooxygenase-2 119 The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 31
O5-4 O6-2 HBV HBx c-myc Early Molecular Response 119 1 1 1 2 1 3 1 1 1 1 1 2 1 1 2 3 O5-5 Liquid biopsy 120 15 00 15 45 6 1 O6-1 121 1 2 1 1 1 1 1 1 1 2 URI1 121 11 17 ( ) 2 1 1,2 2 1 1 2 O6-3 122 1 1 1 1 1 1 2 3 4 1 1 2 3 4 O6-4 Tenascin-C Annexin-A2 122 O6-5 123 1 2 1 1 2 O6-6 123 1,2,3,4 1 4 1 2 3 4 32 29
11 17 ( ) 2 15 45 16 20 7 2 O7-1 Nrf2 124 O7-2 124 1 2 3 3 1 2 3 O7-3 125 1 1 1 1 1 1 1 1 2 1 1 2 O7-4 2,206 nestin single nucleotide polymorphisms 126 1 2 3 4 5 6 7 1 1 2 3 4 5 6 7 O7-5 127 1 2 3 4 5 6 Subhajyoti De 7 Lauren M Rosati 8 Joseph M Herman 8 CA Iacobuzio-Donahue 9 1 2 3 4 5 6 7 8 MD 9 The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 33
11 17 ( ) 11 17 15 00 16 10 2 2 P2-13 X 136 1 1 1 2 1,3 1 2 3 P2-14 Transgelin 136 1 2 1 1 1 1 3 2 2 1 1 2 3 P2-15 Semaphorin3C 137 1,2 1 1,3 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 1 3 3 1 2 3 P2-16 Protocadherin B9 137 1,2 1 1,3 1 1 3 2 1 1 2 3 P2-17 Pterostilbene 138 1 1,2 1 2 1 1 2 P2-18 138 1,2 1,2 1,2 1,3 1 1 1 1 2 3 P2-19 Pterostilbene MAM 139 1,2 1 1 2 2 1 1 2 P2-20 139 P2-21 A 140 34 29
P2-22 140 1 1 1 1 1 1 1 1 1 1 1 2 1 2 P2-23 cell-free DNA 141 1 1 1 1 2 1 3 1 1 1 1 1 1 15 00 16 10 1 2 3 4 1 P4-1 IGF - a nested case-control study 147 1,2 3 4 1,2 2 2 1 5 6 1 2 3 4 5 6 P4-2 147 1,2 1,2 1,2 2 2 1 2 1 2 P4-3 148 1 1 1 1 1 1 1 1 2 1 1 2 P4-4 148 1,2 1,2 1,2 1,3 1 1 2 3 P4-5 149 1,2 1,2 1,3 1,2 1 1 2 3 11 17 ( ) 15 00 16 10 6 2 P6-8 154 P6-9 TFR1 154 1,2 2 1 3 3 4 1,2 1 2 3 4 The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 35
11 17 ( ) P6-10 Rho ARHGEF2 155 P6-11 155 1 1 1 1 1 1 1 2 2 1 1 2 P6-12 SASP 156 1 1 1 1 1 1 1 1 1 1 1 1 1 2 1 2 P6-13 PHGDH 156 P6-14 WHO 157 P6-15 1 157 1 1 2 2 3 3 3 3 3 3 3 3 1 2 3 15 00 16 10 8 2 P8-13 164 1 1 1 3 1 1 1 2 2 1 1 2 3 P8-14 164 1 1 1 1 1 1 1 1 1 1 2 1 1 2 P8-15 DNA -H2AX 165 1 1 1,2 1 1 2 36 29
TLS 165 P8-16 P8-17 166 1,2 1 1 2 1 1 2 P8-18 PD-L2 166 P8-19 CD44v9 167 1,2 1 1 1 1 1 1 1 1 2 1 1 2 P8-20 167 1,2 3 1 1 2 2 2 3 1 1 2 3 P8-21 Recycling endosome RAB11A HER2 168 1,2 3 3 1 1 1 1 1 1 3 1 1 2 3 P8-22 PDX 168 1 2 3 1 1 1 1 2 3 P8-23 5-FU 169 11 17 ( ) The 29th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis 37